Zai Lab Announces NDA Acceptance Of Repotrectinib For Patients With ROS1-Positive NSCLC By China's NMPA
Portfolio Pulse from Bill Haddad
Zai Lab has announced that China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Repotrectinib for patients with ROS1-Positive NSCLC. This is a significant step for Zai Lab in their efforts to bring this drug to market.
June 28, 2023 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zai Lab's stock may see positive movement as the NMPA's acceptance of the NDA for Repotrectinib is a significant step towards the drug's market release.
The acceptance of the NDA by the NMPA is a crucial regulatory step for Zai Lab's Repotrectinib. This news indicates progress in the drug's development and potential market release, which could positively impact Zai Lab's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100